Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.


home / news releases / GLAXF - 23andMe: Holiday Miracles Not Enough Growth Path Too Expensive

GLAXF - 23andMe: Holiday Miracles Not Enough Growth Path Too Expensive

GlaxoSmithKline Plc
  • 23andMe is a consumer-facing genetics testing company, one of the largest in terms of genetic databases.
  • However, there are some glaring financial risks to consider if you want to invest in the company: slow test kit growth and profitability.
  • New attempts to move towards drug development and primary care telehealth may drive revenues, it will continue to be unprofitable.
  • For these reasons, I would recommend avoiding the company.

For further details see:

23andMe: Holiday Miracles Not Enough, Growth Path Too Expensive
Stock Information
Company Name: GlaxoSmithKline Plc
Stock Symbol: GLAXF
Market: OTC
Website: gsk.com
Menu
GLAXF GLAXF Quote GLAXF Short GLAXF News GLAXF Articles GLAXF Message Board
Get GLAXF Alerts

News, Short Squeeze, Breakout and More Instantly...